VEGFA and hepatocellular carcinoma: Notably, patients with steatotic HCC, as confirmed via chemical-shift MR imaging, exhibited significantly prolonged progression-free survival (PFS) upon receiving a combined immunotherapy regimen involving anti-PD-L1 and anti-VEGF antibodies [58].